BioRegenx Balance Sheet Health
Financial Health criteria checks 4/6
BioRegenx has a total shareholder equity of $13.6M and total debt of $2.2M, which brings its debt-to-equity ratio to 15.9%. Its total assets and total liabilities are $17.4M and $3.8M respectively.
Key information
15.9%
Debt to equity ratio
US$2.15m
Debt
| Interest coverage ratio | n/a |
| Cash | US$70.08k |
| Equity | US$13.56m |
| Total liabilities | US$3.80m |
| Total assets | US$17.36m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BRGX's short term assets ($371.0K) do not cover its short term liabilities ($3.5M).
Long Term Liabilities: BRGX's short term assets ($371.0K) exceed its long term liabilities ($282.3K).
Debt to Equity History and Analysis
Debt Level: BRGX's net debt to equity ratio (15.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BRGX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BRGX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BRGX is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 10.4% per year.